64 related articles for article (PubMed ID: 38646542)
1. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis.
Dong HJ; Yang CY
Clin Respir J; 2024 May; 18(5):e13756. PubMed ID: 38725310
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis.
Wei C; Du X; Hu J; Dong Y; Chen Y; Cao B
Crit Rev Oncol Hematol; 2024 Jun; 198():104082. PubMed ID: 37532103
[TBL] [Abstract][Full Text] [Related]
4. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Waser NA; Quintana M; Schweikert B; Chaft JE; Berry L; Adam A; Vo L; Penrod JR; Fiore J; Berry DA; Goring S
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38521542
[TBL] [Abstract][Full Text] [Related]
5. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
6. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Sathiyapalan A; Baloush Z; Ellis PM
Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
[TBL] [Abstract][Full Text] [Related]
8. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
Feldman H; Sepesi B; Leung CH; Lin H; Weissferdt A; Pataer A; William WN; Walsh GL; Rice DC; Roth JA; Mehran RJ; Hofstetter WL; Antonoff MB; Rajaram R; Gibbons DL; Lee JJ; Heymach JV; Vaporciyan AA; Swisher SG; Cascone T
J Thorac Cardiovasc Surg; 2024 Apr; 167(4):1444-1453.e4. PubMed ID: 37816395
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysis.
Mi D; Ren W; Yang K
Indian J Med Res; 2016 May; 143(Supplement):S1-S10. PubMed ID: 27748271
[TBL] [Abstract][Full Text] [Related]
10. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
Zhao R; Guan X; Zhang P; Liu Y; Xu Y; Sun C; Qiu S; Zhu W; Yang Z; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):175. PubMed ID: 38573518
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study.
Tsuboi M; Murakami H; Harada H; Sobue T; Kato T; Atagi S; Tokito T; Mio T; Adachi H; Kozuki T; Sone T; Seike M; Toyooka S; Kitagawa H; Koto R; Yamazaki S; Horinouchi H
Thorac Cancer; 2024 May; ():. PubMed ID: 38812106
[TBL] [Abstract][Full Text] [Related]
12. The nutrition-related adverse events associated with immune checkpoint inhibitor treatment for patients with non-small cell lung cancer: A systematic review.
Graham KL; Carty D; Poulter SP; Blackman C; Dunstan OG; Milton TL; Ferguson C; Smith K; Van Dijk E; Jongebloed D; Loeliger J; Baguley BJ
Nutr Diet; 2024 May; ():. PubMed ID: 38804022
[TBL] [Abstract][Full Text] [Related]
13. Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer.
Lin F; Chen Y; Huang B; Ruan S; Lin J; Chen Z; Huang C; Zhao B
Front Pharmacol; 2024; 15():1391562. PubMed ID: 38783944
[TBL] [Abstract][Full Text] [Related]
14. Multimodal Treatment of Resectable Esophageal Cancer.
Waters J; Sewell M; Molena D
Ann Thorac Surg; 2024 May; ():. PubMed ID: 38777248
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial.
Olivier T; Prasad V
Transl Oncol; 2024 Jul; 45():101959. PubMed ID: 38621314
[TBL] [Abstract][Full Text] [Related]
16. A commentary on "Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, large-sample informatics study".
Yang J; Wang Z; Deng H
Int J Surg; 2024 May; ():. PubMed ID: 38814315
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
19. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
